As the s-APEX1 level was significantly higher in the HCC, CC, and ccRCC groups than in the healthy control group when the HBV DNA (+) group was excluded, we performed ROC analysis to identify the appropriateness of s-APEX1 as a diagnostic marker for the three cancers (Figure 4). This evidence concerns the gene APEX1 and cholangiocarcinoma.